FREQ - Frequency Therapeutics Inc Stock Price, Fair Value and News

$0.280.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FREQ Price Action

Last 90 days

16.7%

Trailing 12 Months

-17.6%

FREQ RSI Chart

FREQ Valuation

Market Cap

2.6M

Price/Earnings (Trailing)

-0.03

Price/Sales (Trailing)

1.24

EV/EBITDA

0.26

Price/Free Cashflow

-0.04

FREQ Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FREQ Fundamentals

FREQ Revenue

Revenue (TTM)

2.3M

FREQ Earnings

Earnings (TTM)

-88.4M

Earnings Growth (Yr)

13.99%

Earnings Growth (Qtr)

29.91%

FREQ Profitability

EBT Margin

-3888.73%

Return on Equity

-89.28%

Return on Assets

-54.73%

Free Cashflow Yield

-2.7K%

FREQ Investor Care

Shares Dilution (1Y)

0.52%

Diluted EPS (TTM)

-9.4

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	0	0	8.2M	2.3M
2021	34.4M	35.3M	24.0M	14.1M
2020	36.8M	44.7M	31.7M	37.0M
2019	0	0	0	28.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Frequency Therapeutics Inc

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

CEO	Mr. David L. Lucchino
WEBSITE	frequencytx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	46

Frequency Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Frequency Therapeutics Inc? What does FREQ stand for in stocks?

FREQ is the stock ticker symbol of Frequency Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Frequency Therapeutics Inc (FREQ)?

As of Wed Dec 03 2025, market cap of Frequency Therapeutics Inc is 2.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FREQ stock?

You can check FREQ's fair value in chart for subscribers.

Is Frequency Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FREQ is over valued or under valued. Whether Frequency Therapeutics Inc is cheap or expensive depends on the assumptions which impact Frequency Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FREQ.

What is Frequency Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, FREQ's PE ratio (Price to Earnings) is -0.03 and Price to Sales (PS) ratio is 1.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FREQ PE ratio will change depending on the future growth rate expectations of investors.